OKYO Pharma
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
14/15 Conduit St Fl 4, London, Greater L...Phone Number
+44 2074952379Website
www.okyopharma.comRevenue
<$5 MillionStock Symbol
OKYOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About OKYO Pharma
OKYO Pharma is a biopharmaceutical company developing therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. They are based in London, United Kingdom.Explore more
OKYO Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OKYO Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when OKYO Pharma launches new products
Click to see if OKYO Pharma had a recent Job posting/layoffs
Check if OKYO Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on OKYO Pharma recently announced quarterly report
Funding: Get notified immidiatlly once OKYO Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at OKYO Pharma
Website visits: Recent activity has been detected on your website
Check out if OKYO Pharma is spiking on competitors!
OKYO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to OKYO Pharma
Compare insights from companies similar to OKYO Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OKYO Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OKYO Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OKYO Pharma.
OKYO Pharma financials insights
Gather financial insights about OKYO Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Stock Offering
$2.5M
2025
Other Financing Round
$1.4M
Other Financing Round
$1.9M
OKYO Pharma Tech Stack
A closer look at the technologies used by OKYO Pharma
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Person-Based
Person-Based
OKYO Pharma News & Media
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.OKYO Pharma Announces Purchase of Shares by Chairman
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his toOKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities and Exchange Commission, while outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding OKYO Pharma
Sign Up For FreeTo access detailed company insights
OKYO Pharma is a biopharmaceutical company developing therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. They are based in London, United Kingdom.... Read More
